Harvard Apparatus Regenerative Technology (HRGN) Price & Analysis

Compare

104 Followers

HRGN Stock Chart & Stats

$1.82

$0.07(2.66%)

At close: Jan 07 4:00 PM EST

$1.82

$0.07(2.66%)

Day’s Range― - ―

52-Week Range$0.94 - $2.55

Previous CloseN/A

Volume1.21K

Average Volume (3M)1.13K

Market Cap

$30.85M

Enterprise Value$28.44M

Total Cash (Recent Filing)$1.32M

Total Debt (Recent Filing)$224.00K

Price to Earnings (P/E)―

Beta0.12

Next Earnings

May 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.11

Shares Outstanding17,580,744

10 Day Avg. Volume797

30 Day Avg. Volume1,125

Financial Highlights & Ratios

PEG Ratio0.25

Price to Book (P/B)13.68

Price to Sales (P/S)0.00

P/FCF Ratio-9.08

Enterprise Value/Market Cap0.92

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-78.12

Enterprise Value/Ebitda-4.38

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Stronger Equity BaseA low absolute debt load relative to equity gives the company a structurally low leverage profile. That reduces near‑term solvency risk and preserves optionality for R&D and strategic moves, providing a firmer balance‑sheet base while commercialization is pursued.

Incremental Capital From Private PlacementThe recent $0.7M private placement meaningfully extends near‑term runway for development and regulatory activities. As a structural benefit, this funding allows continued program advancement without immediate revenue, supporting execution while longer‑term financing is arranged.

Lean Organizational StructureA very small workforce implies low fixed overhead and operational agility common in early‑stage biotech. Structurally, a lean cost base can stretch available capital, enable faster decision making in development programs, and reduce non‑core administrative burden.

Bears Say

Zero Revenue / Persistent Operating LossesThe company remains pre‑commercial with no reported revenue and sustained large operating losses. Over the medium term this prevents internal funding of development, increases execution risk for commercialization, and forces dependence on external financing to sustain operations.

Chronic Negative Cash Flow And Rising BurnConsistent negative operating and free cash flow, with free cash flow deteriorating in 2024, signals structural cash‑burn that undermines sustainability. This persistent outflow limits ability to invest in trials or scale operations without recurrent capital raises.

Ongoing Reliance On External Financing / Dilution RiskThe need for incremental private placements highlights a structural dependence on external capital. With no revenue and negative cash flow, recurring financings are likely, increasing shareholder dilution risk and constraining strategic flexibility over the medium term.

Harvard Apparatus Regenerative Technology News

Harvard Apparatus Regenerative Tech Announces Private Stock Placement

An announcement from Harvard Apparatus Regenerative Technology ( ($HRGN) ) is now available. On December 30, 2025, Harvard...

2M ago

HRGN

Harvard Apparatus Raises $2M Through Private Placement

Harvard Apparatus Regenerative Technology ( ($HRGN) ) has issued an announcement. On July 11, 2025, Harvard Apparatus Regenerative...

8M ago

HRGN

Harvard Apparatus Holds 2025 Annual Stockholders Meeting

The latest update is out from Harvard Apparatus Regenerative Technology ( ($HRGN) ). On June 20, 2025, Harvard...

8M ago

HRGN

Harvard Apparatus Appoints Mao Zhang to Board of Directors

Harvard Apparatus Regenerative Technology (HRGN) has issued an update. Mao Zhang, the CEO of Stellars Capital, has been...

2y ago

HRGN

HRGN FAQ

What was Harvard Apparatus Regenerative Technology’s price range in the past 12 months?

Harvard Apparatus Regenerative Technology lowest stock price was $0.94 and its highest was $2.55 in the past 12 months.

What is Harvard Apparatus Regenerative Technology’s market cap?

Harvard Apparatus Regenerative Technology’s market cap is $30.85M.

When is Harvard Apparatus Regenerative Technology’s upcoming earnings report date?

Harvard Apparatus Regenerative Technology’s upcoming earnings report date is May 18, 2026 which is in 74 days.

How were Harvard Apparatus Regenerative Technology’s earnings last quarter?

Harvard Apparatus Regenerative Technology released its earnings results on Aug 19, 2025. The company reported -$0.114 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.114.

Is Harvard Apparatus Regenerative Technology overvalued?

According to Wall Street analysts Harvard Apparatus Regenerative Technology’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Harvard Apparatus Regenerative Technology pay dividends?

Harvard Apparatus Regenerative Technology does not currently pay dividends.

What is Harvard Apparatus Regenerative Technology’s EPS estimate?

Harvard Apparatus Regenerative Technology’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Harvard Apparatus Regenerative Technology have?

Harvard Apparatus Regenerative Technology has 17,580,744 shares outstanding.

What happened to Harvard Apparatus Regenerative Technology’s price movement after its last earnings report?

Harvard Apparatus Regenerative Technology reported an EPS of -$0.114 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.885%.

Which hedge fund is a major shareholder of Harvard Apparatus Regenerative Technology?

Currently, no hedge funds are holding shares in HRGN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. Its lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair. It also sells consumer health products that focuses on personal healthcare, including dietary supplements. Harvard Apparatus Regenerative Technology Inc. was formerly known as Biostage, Inc. and changed its name to Harvard Apparatus Regenerative Technology Inc. in July 2023. The company was founded in 2009 and is headquartered in Holliston, Massachusetts.